Adverse effects sufficient to stop treatment · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate probably leads to higher adverse effects severe enough to stop treatment** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Caesarean section · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in mode of birth (caesarean section)** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Postpartum haemorrhage · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in postpartum haemorrhage** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Any breastfeeding at hospital discharge · women at risk of preterm birth (< 34 weeks' gestation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Women’s views of treatment** · women at risk of preterm birth (< 34 weeks' gestation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cerebral palsy · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate leads to lower cerebral palsy (up to 2 years' corrected age)** compared with placebo (outcomes (high certainty).
2 findings from 1 review
Major disability by 18 to 24 months corrected age (aligned definition) · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in major neurodevelopmental disability (up to 2 years' corrected age)** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Intraventricular haemorrhage, Papile grade 3/4 · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate probably leads to lower severe intraventricular haemorrhage (grade 3 or 4) (newborn/infant)** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in chronic lung disease/bronchopulmonary dysplasia (newborn/infant)** compared with placebo (outcomes (low certainty).
1 finding from 1 review
Death (fetal, neonatal, or later (up to school age))** · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in death (fetal, neonatal, or later (up to school age))** compared with placebo (outcomes (low certainty).
1 finding from 1 review
Mortality within the longest · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with cardiopulmonary bypass
Prophylactic corticosteroids showed no clear difference in all‐cause mortality (during the index hospital admission, or within… compared with placebo or no corticosteroids (low certainty).
1 finding from 1 review
Cardiac complications (as defined by study authors, including cardiac compromise and fatal and non‐fatal myocardial infarction, defined as ECG changes, echocardiological changes, or disproportionate elevation of troponins, during the index hospita... · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with cardiopulmonary bypass
Prophylactic corticosteroids may leads to higher cardiac complications (as defined by study authors, including… compared with placebo or no corticosteroids (low certainty).
1 finding from 1 review
Pulmonary complications (as defined by study authors, including pneumonia, embolism, reduced pulmonary function, prolonged ventilation, and pleural effusion, during the index hospital admission) · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with cardiopulmonary bypass
Prophylactic corticosteroids may leads to lower pulmonary complications (as defined by study authors, including… compared with placebo or no corticosteroids (low certainty).
1 finding from 1 review
Infectious complications · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with cardiopulmonary bypass
Prophylactic corticosteroids may leads to lower infectious complications (as defined by study authors, including… compared with placebo or no corticosteroids (low certainty).
1 finding from 1 review
Gastrointestinal bleeding · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with cardiopulmonary bypass
Prophylactic corticosteroids showed no clear difference in gastrointestinal (GI) bleeding (as defined by study authors,… compared with placebo or no corticosteroids (low certainty).
1 finding from 1 review
Renal failure · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with cardiopulmonary bypass
Prophylactic corticosteroids showed no clear difference in renal failure (as defined by study authors, including dialysis,… compared with placebo or no corticosteroids (low certainty).
1 finding from 1 review
Length of stay · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with cardiopulmonary bypass
1 finding from 1 review
Death (all causes) · people with diabetes and kidney disease
Angiotensin‐converting‐enzyme inhibitors showed no clear difference in all‐cause death Median compared with placebo or no treatment (low certainty).
1 finding from 1 review
Doubling of SCr Median · people with diabetes and kidney disease
Angiotensin receptor blockers may leads to lower doubling of SCr Median compared with placebo or no treatment (low certainty).
1 finding from 1 review
Fatal or nonfatal stroke · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in fatal or nonfatal stroke Median compared with placebo or no treatment (low certainty).
1 finding from 1 review